Oncometabolites (Succinate/Fumarate/2-HG) and Epigenetic Crosstalk
One Target Family
| Enzyme family | Function | Inhibited by |
|---|---|---|
| TET1/2/3 | 5mC → 5hmC and further oxidation | 2-HG (D), succinate, fumarate |
| KDM2–KDM7 (JmjC) | Histone lysine demethylation | 2-HG, succinate, fumarate |
| PHD1/2/3 (EGLN) | HIF prolyl hydroxylation | Succinate, fumarate, 2-HG at high concentration |
| FTO, ALKBH5 | RNA m6A demethylation | 2-HG, succinate (reported) |
| Aspartyl/asparaginyl hydroxylases | Notch and other substrates | 2-HG |
Important distinction. These enzymes all use α-ketoglutarate as a co-substrate and Fe(II) as a cofactor, and the oncometabolites act as competitive inhibitors with respect to α-KG. That shared mechanism is why a mutation in SDH, FH or IDH produces similar epigenetic phenotypes, and why the phenotypes are not specific to the mutated gene.
Part 1 — Which Metabolite, Which Consequence
| Metabolite | Genetic lesion | Primary epigenetic consequence | Secondary |
|---|---|---|---|
| D-2-HG | IDH1/2 neomorphic mutation | DNA hypermethylation; blocked differentiation | Histone hypermethylation; PHD inhibition at high levels |
| Succinate | SDHA/B/C/D mutation | DNA and histone hypermethylation | HIF stabilisation via PHD inhibition |
| Fumarate | FH mutation | DNA and histone hypermethylation | KEAP1 succination → NRF2 activation |
| L-2-HG | L2HGDH loss (rare) | Neurological, not typically oncogenic | — |
Important distinction. D-2-HG and L-2-HG are different molecules with different sources and different clinical associations. The oncogenic one is D-2-HG from mutant IDH. Any measurement that does not resolve the enantiomers is reporting a mixture, and the interpretation is undefined.
Part 2 — Concentration and Compartment
| Requirement | Typical value | Why it matters |
|---|---|---|
| Intracellular 2-HG in IDH-mutant cells | Millimolar | High enough to inhibit TET and KDM substantially |
| Intracellular 2-HG in IDH-wild-type cells | Micromolar | Far below the inhibition range |
| α-KG concentration | Millimolar (mitochondrial), lower cytosolic | The ratio to 2-HG, not the absolute value, sets inhibition |
| Succinate in SDH-deficient cells | Millimolar (mitochondrial) | Cytosolic concentration is lower and less certain |
| Fumarate in FH-deficient cells | Millimolar | Succination of KEAP1 is detectable at these levels |
Caveat on the succinate argument. Succinate accumulates primarily in the mitochondrial matrix, and the cytosolic concentration that reaches nuclear dioxygenases is lower and technically harder to measure. A whole-cell "succinate increased" measurement cannot establish that nuclear TET activity fell; the epigenetic readout, or a nuclear metabolite measurement, is required.
The same caution applies in reverse to fumarate: its effects include succination of cysteine residues, which is a covalent modification rather than competitive inhibition, and the two mechanisms have different dose–response shapes.
Part 3 — The Epigenetic Readouts
| Readout | What it reports | Method |
|---|---|---|
| 5mC and 5hmC | DNA methylation and its oxidised derivative | Bisulfite or enzymatic sequencing; LC-MS of hydrolysed DNA |
| Histone methylation (H3K9me3, H3K27me3, H3K4me3) | Demethylase activity | Immunoblot, ChIP-seq, mass spectrometry |
| m6A on RNA | RNA demethylase activity | m6A-seq; LC-MS of nucleosides |
| Differentiation markers | Functional consequence | Expression and morphology |
| Global methylation by LC-MS | Total 5mC/5hmC ratio | Quantitative, no locus resolution |
Readout note. Global 5mC measured by LC-MS is quantitative and cheap, and it reports the aggregate consequence without locus resolution. For a mechanism claim, locus-specific data (sequencing) plus a functional consequence (differentiation block, gene expression) is the stronger package.
Part 4 — Establishing Causality
| Level | Claim | Requirement |
|---|---|---|
| Correlation | Metabolite and methylation change together | Both measured in the same cells |
| Dose | The metabolite causes the change | Titration; or exogenous cell-permeable metabolite |
| Genetic | The lesion is required | Re-expression of wild-type enzyme; or mutation reversion |
| Reversal | Removing the metabolite reverses the mark | IDH inhibitor with 2-HG and methylation measured |
| Functional | The mark mediates the phenotype | Demethylase perturbation reproducing the phenotype |
Caveat on cell-permeable metabolites. Octyl-2-HG and dimethyl-succinate are used to raise intracellular concentrations, and the concentrations required are usually millimolar. Effects at those concentrations may reflect osmotic or metabolic effects rather than specific dioxygenase inhibition; a comparison with a structurally similar but non-inhibitory analogue is the appropriate control.
Part 5 — Model Requirements and Recurring Failures
| Requirement | Why |
|---|---|
| Enantiomer-resolved 2-HG | D and L are different |
| α-KG measured alongside | Inhibition depends on the ratio |
| Compartment considered | Whole-cell averages mitochondrial and cytosolic pools |
| Wild-type comparator | Isogenic, ideally |
| Methylation measured quantitatively | Global and locus-specific |
| Functional readout | Methylation alone is a mark |
Recurring failures:
- • Total 2-HG reported without enantiomer resolution.
- • Whole-cell succinate used to infer nuclear PHD or TET inhibition.
- • Methylation reported without α-KG, so the ratio is unknown.
- • Exogenous metabolite effects attributed to specific inhibition, without an analogue control.
- • A single histone mark reported as "epigenetic reprogramming".
- • Wild-type and mutant compared across different lines, confounding genotype with background.
- • IC50 values from recombinant enzymes applied to cells, where concentrations differ.
Part 6 — Where This Article Connects
This is the signalling article of the mitochondrial cluster, and it is where the TCA cycle becomes a chromatin modifier. It connects to the methionine and one-carbon articles, because DNA methylation depends on both the mark's removal (TET) and its maintenance (SAM), and to the respiratory chain article, because the mutations that produce these metabolites are ETC and TCA lesions.
If you need oncometabolite concentrations measured with enantiomer resolution and compartment inference, we can scope the analysis with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Oncometabolite concentrations, compartment distribution and downstream effects vary with genotype, cell type and culture conditions. The values here are ranges from the literature, not thresholds for a specific model.
An epigenetic mark correlated with a metabolite does not establish that the metabolite caused it, and inhibition of a recombinant enzyme does not establish inhibition in the cell.
Scientific interpretation and experimental design
- • One target family, three metabolites. The phenotypes overlap for a reason.
- • D and L differ. Resolve them.
- • The ratio to α-KG sets inhibition, not the absolute value.
- • Compartment matters for succinate.
- • Marks are not mechanisms. Add a functional readout.
- • Analogue controls for permeable metabolites.
Selected references for further reading
- • Ward PS, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225–234.
- • Xiao M, et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes & Development. 2012;26:1326–1338.
- • Sciacovelli M, Frezza C. Oncometabolites: unconventional triggers of oncogenic signalling cascades. Free Radical Biology and Medicine. 2016;100:175–181.
- • Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Development. 2013;27:836–852.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »